GW Pharma has named Scott Giacobello as chief financial officer (CFO) of the group.
Giacobello, who brings 25 years of finance and operational experience to the firm, was most recently CFO for clinical stage biopharma Chase Pharmaceuticals, until its acquisition by Allergan late last year.
At GW, takes over over from Adam George, who has held the position of CFO at the firm since 2012.
George is now managing director - UK at GW, stepping into a newly-created executive role with broad leadership responsibilities for UK operations.
Both will report to the group’s chief executive Justin Gover.
“These important leadership appointments reflect GW’s continuing evolution into a transatlantic commercial-stage biopharmaceutical company,” Gover said.
“In anticipation of Epidiolex approval and launch, and with GW now solely listed on Nasdaq, we expect to transition from being a Foreign Private Issuer reporting under IFRS to become a domestic registrant reporting under USGAAP and in US dollars in future years.
“Giacobello’s “significant financial and accounting expertise will be a major asset to the organisation as we make that shift,” he added.